Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Vaxcyte
Vaxcyte
Vaxcyte's 'stunning' 31-valent pneumococcal vaccine win against Pfizer's Prevnar 20 has analysts thinking big
Fierce Biotech
Tue, 09/3/24 - 11:10 am
Vaxcyte
clinical trials
vaccines
pneumococcal disease
VAX-31
Vaxcyte Up on Pneumococcal Conjugate Vaccine Data
Zacks.com
Wed, 04/19/23 - 10:23 am
Vaxcyte
vaccines
clinical trials
pneumococcal disease
VAX-24
Vaxcyte strengthens case for experimental pneumococcal vaccine
BioPharma Dive
Tue, 04/18/23 - 10:06 am
Vaxcyte
vaccines
clinical trials
pneumococcal disease
Biotech heads towards big catalysts
EP Vantage
Tue, 03/28/23 - 10:24 am
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win
Endpoints
Mon, 10/24/22 - 11:19 am
Vaxcyte
vaccines
VAX-24
pneumococcal disease
Pfizer
Prevnar 20
clinical trials
Slaoui steps down from two more biotechs after harassment claim
BioPharma Dive
Thu, 03/25/21 - 11:48 am
Moncef Slaoui
GSK
Galvani
Vaxcyte
Centessa Pharmaceuticals
sexual harassment
The biotech IPOs keep coming at chart-topping levels — with no slowdown in sight
Endpoints
Fri, 06/19/20 - 11:27 am
biotech
IPOs
Repare Therapeutics
Forma Therapeutics
Avidity Biosciences
Vaxcyte
SK Biopharmaceuticals
Generation Bio
Royalty Pharma
The pandemic IPOs keep rolling, as Generation, Avidity, Vaxcyte each claim 200M+
Endpoints
Fri, 06/12/20 - 10:43 am
biotech
IPOs
Generation Bio
Avidity Biosciences
Vaxcyte
Burning Rock